Catalyst Dossier · compiled by CeliA 🧫

Alvotech (ALVO)

Biological Products, (No Diagnostic Substances) · market cap $1.2B · as of 2026-07-03

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-12

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Alvotech (ALVO) is an Icelandic-rooted biosimilar developer with ~1,012 employees and a market cap of approximately $1.235B at ~$3.58/share. The company operates a broad Phase 3 biosimilar pipeline spanning immunology, ophthalmology, and bone health, with two near-term FDA PDUFA dates for vedolizumab biosimilars in late 2026 and mid-2027. Dilution risk is flagged as elevated at 27% over the prior year, and financial transparency is limited given undisclosed cash, runway, and net debt figures.

The catalyst path

2026-08-12Earningsimp 5/10
2026-12-08 (est.)PDUFA · AVT16 (vedolizumab biosimilar)imp 8/10
2027-06-03 (est.)PDUFA · Entyvio biosimilarimp 8/10

Pipeline

Asset	Phase	Indication
Adalimumab	Phase 3	Plaque Psoriasis
AVT05 (proposed biosimilar to golimumab)	Phase 3	Rheumatoid Arthritis
AVT03	Phase 3	Osteoporosis, Postmenopausal
Stelara	Phase 3	Psoriasis
Adalimumab originator	Phase 3	Plaque Psoriasis
AVT06 (proposed aflibercept biosimilar)	Phase 3	Neovascular (Wet) AMD
AVT29 (proposed aflibercept HD biosimilar)	Phase 3	Diabetic Macular Edema

Price & technical context

3-month

+4.4%

6-month

-28.0%

12-month

-60.7%

52-wk range

$3.00–$9.81

vs 50-day MA

+0.4%

vs 200-day MA

-28.1%

Realized vol

75.2%

Max drawdown

-79.3%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ALVO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.